Alkermes Buys Size With Purchase Of Elan Drug Delivery Unit
This article was originally published in The Pink Sheet Daily
The mid-sized biotech makes a transformational deal with the purchase of Elan's drug delivery unit.
You may also be interested in...
Alkermes Inc's acquisition of Elan Corp.'s Elan Drug Technology, announced May 9, more than doubles the revenues of one of the biopharma industry's most successful reformulation companies, and provides it with additional cash flow it needs to pursue a slate of innovative compounds it is developing.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.